The current results indicated that NKp30 overexpression in the absence of IL-2 supplementation could improve NK cytotoxicity against THP-1 AML cells expressing moderate levels of the NKp30 ligand B7-H6. The gene discussed is NCR3LG1; the disease is acute myeloid leukemia.